NovoCure Reports Positive Phase 3 METIS Trial Results for Brain Metastases from Lung Cancer
Key Insights
NovoCure (search) announced positive final results from its pivotal Phase 3 METIS trial, showing that Tumor Treating Fields therapy significantly delayed tumor progression in brain metastases from lung cancer.
The results were presented at the ASTRO Annual Meeting and are set to be published in a top medical journal, marking a key clinical milestone for the company.
The METIS trial success, along with the ongoing PANOVA-3 trial for pancreatic cancer, positions NovoCure (search) for potential regulatory approvals and market expansion beginning in 2026.
NovoCure (search) has announced positive final results from its pivotal Phase 3 METIS trial, demonstrating that Tumor Treating Fields (TTFields) therapy significantly delayed tumor progression in patients with brain metastases from non-small cell lung cancer. The results were presented at the ASTRO Annual Meeting and are scheduled for publication in a top-tier medical journal.
Clinical Trial Outcomes
The Phase 3 METIS trial represents a significant clinical milestone for NovoCure (search)'s TTFields technology in treating brain metastases from lung cancer. The therapy showed statistically significant delays in tumor progression, marking the first positive Phase 3 results for this indication. This achievement comes as part of NovoCure's broader clinical development program aimed at expanding TTFields therapy beyond its current approved indication in glioblastoma.
Market Expansion Strategy
The METIS trial success positions NovoCure (search) for potential regulatory approvals and substantial market expansion beginning in 2026. The company is simultaneously advancing its PANOVA-3 trial for pancreatic cancer, creating multiple pathways for growth in the oncology market. These developments could drive significant topline revenue growth as global cancer incidence continues to rise with an aging population.
Real-world adoption of TTFields therapy is showing positive trends in both academic and community settings. Positive retrospective studies, including data from the Mayo Clinic in glioblastoma patients, suggest building physician confidence and integration into standard care protocols. This growing acceptance may translate into higher device utilization rates and more stable recurring revenues over time.
Financial Performance and Valuation
Despite the clinical progress, NovoCure (search)'s stock performance has been challenging. The company's shares have experienced negative returns of -14% over one year and -81% over three years, though they gained 11% over the past month following the trial announcement. Current share price of $14.66 represents a substantial discount to analyst fair value estimates of $27.19, suggesting the stock may be undervalued by approximately 46-50%.
Market Challenges
The company continues to face headwinds from slower-than-expected U.S. prescription growth and persistent reimbursement challenges. These factors could potentially undermine confidence in NovoCure (search)'s long-term revenue outlook and may impact the timeline for achieving profitability. The success of the expanded indications will largely depend on overcoming these adoption barriers and securing broad reimbursement coverage for TTFields therapy across multiple cancer types.